Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
An alternate pathway for bilirubin catabolism
FEBS Letters, 1980 C.R. Krishna Murti +2 more
openaire +3 more sources
Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction. [PDF]
Nat Commun, 2023 Sülzen H +12 more
europepmc +1 more source
C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by Salmonella montevideo. [PDF]
, 1986 Keith A. Joiner +3 more
openalex +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source
Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases. [PDF]
Immunol Rev, 2023 Rodríguez de Córdoba S.
europepmc +1 more source
Factor B, the complement alternative pathway serine proteinase, is a major constitutive protein synthesized and secreted by resident and elicited mouse macrophages. [PDF]
, 1985 John S. Sundsmo +4 more
openalex +1 more source
Molecular Oncology, EarlyView.A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul +11 more
wiley +1 more source
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19. [PDF]
Immunology, 2023 Siggins MK +10 more
europepmc +1 more source
In vitro activation of the alternative pathway of complement by settled grain dust
, 1978 Stephen A. Olenchock +5 more
openalex +1 more source